Unique
microencapsulation
technology
.1% tretinoin and 3% BPO combined for coapplication1,2
Watch the video below to hear an expert discuss how it works.
Core-shell structure
Layered silica shells individually encapsulate .1% tretinoin & 3% BPO.1,3
Maintained stability
The shells keep the ingredients separated, protecting tretinoin from oxidation and degradation by BPO.3
Increased tolerability
When applied, the shells, acting as a barrier between the active ingredients and the skin, gradually release tretinoin & BPO.3*
.1% tretinoin & 3% BPO: Finally in 1 fixed dose with favorable tolerability1,2,4
BPO=benzoyl peroxide.
The mechanism of action of tretinoin & BPO in treating acne is unknown.1
References: 1. TWYNEO (tretinoin and benzoyl peroxide) cream, 0.1%/3% [Prescribing Information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2021. 2. Sol-Gel Technologies Ltd. Sol-Gel Technologies announces FDA approval of TWYNEO® Sol-Gel Advanced Topical Therapy. July 27, 2021. Accessed August 20, 2021. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor 3. Erlich M, Arie T, Koifman N, Talmon Y. Structure elucidation of silica-based core-shell microencapsulated drugs for topical applications by cryogenic scanning electron microscopy. J Colloid Interface Sci. 2020;579:778-785. doi:10.1016/j.jcis.2020.06.114 4. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-05; June 5, 2020.